Bone Abstracts

Sclerostin is a major negative regulator of osteoblastic activity. Serum sclerostin has a weak positive association with BMD but contradictory results have been described concerning associations with fractures. These contradictions could be explained by the fact that serum sclerostin does not reflect its action in bone. In this study we question whether serum sclerostin is associated with its expression in bone. In addition we aimed to detect associations between sclerostin in...

Introduction: Cardiovascular disease and osteoporosis have often been reported to coexist in older people. However, the literature is conflicting regarding size and indeed direction of the association. The aim of the present study was therefore to assess associations between the Framingham general cardiovascular risk score and bone characteristics in a cohort of older adults.Methods: We studied 374 men and 379 women, born 1931–1939, who participated...

Fracture outpatient (FO) clinics aim to identify individuals at high fracture risk. Identification of individuals at high fracture risk has been improved since the introduction of vertebral fracture assessment (VFA). Unfortunately, participation rates in FO clinics are often low.The aim of this study is to i) assess the contributory value of VFA in addition to BMD measurements in identifying individuals with high fracture risk; ii) assess characteristics...

Background: Puberty is highly important for the accumulation of bone mass. Bone turnover and bone mineral density can be affected in transgender adolescents when puberty is postponed by gonadotropin-releasing hormone analogues (GnRHa), followed by treatment with cross-sex hormone therapy (CSHT).Objective: To investigate the effect of GnRHa and CSHT on bone turnover markers (BTMs) and bone mineral apparent density (BMAD) in transgender adolescents.<p ...

Background: In postmenopausal osteoporosis, a loss of bone volume due to increased bone turnover is accompanied by a higher volume of bone marrow adipose tissue (BMAT). If this static relationship is based on a functional relationship, BMAT is a potential target for treating osteoporosis. While it is known that estrogen can reduce BMAT, it is still unknown whether raloxifene – a selective estrogen receptor modulator – can also reduce BMAT.Objec...